AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03762473
Drug: Study Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
Trial: NCT03762473
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.
Trial: NCT00636610
Drug: Modified FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following administration of bevacizumab, patients received oxaliplatin 85 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
Trial: NCT00636610
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following administration of bevacizumab, patients received irinotecan 180 mg/m\^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m\^2 (d,I-racemic form, or 200 mg/m\^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m\^2 administered as an IV bolus, then fluorouracil 2400 mg/m\^2 administered as a continuous IV infusion over 46 hours.
Trial: NCT03759938
Drug: Direct oral anticoagulant (DOAC)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
Trial: NCT00843661
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg pravastatin/day
Trial: NCT03348163
Drug: Current ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.
Trial: NCT03576664
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross-over, randomized, placebo-controlled study.
Trial: NCT02585778
Drug: Antihyperglycemic Drug
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (injectable or inhaled) alone or with other antihyperglycemic drugs as clinically indicated.
Trial: NCT01102101
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
Trial: NCT01313585
Drug: Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device
RxNorm normalized name: salbutamol and beclometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01106079
Drug: Intensive management or Tight control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
Trial: NCT00747032
Drug: NYC 0462 Ointment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
Trial: NCT00747032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
Trial: NCT02477618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02680054
Drug: Insulin, Asp(B28)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
Trial: NCT03053050
Drug: Placebo to match SEL 6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT03053050
Drug: Placebo to match SEL 18 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily
Trial: NCT03656744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets manufactured to mimic HTD1801 tablets
Trial: NCT00104572
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 12 months
Trial: NCT00104572
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 12 months
Trial: NCT04521738
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Trial: NCT01651000
Drug: CTAP101 30 μg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTAP101 30 μg capsule taken daily at bedtime.
Trial: NCT01707329
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
Trial: NCT01899859
Drug: GR-MD-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR-MD-02; galactoarabino-rhamnogalaturonate
Trial: NCT01899859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR-MD-02 Placebo
Trial: NCT02234492
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison of rosuvastatin to no rosuvastatin
Trial: NCT03982186
Drug: Placebo for JNJ-73763989
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for JNJ-73763989 will be administered as subcutaneous injection.
Trial: NCT04267432
Drug: Type 2 collagen
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control group
Trial: NCT03714919
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative oral acetaminophen 15 mg/kg
Trial: NCT03982186
Drug: Placebo for JNJ-56136379
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for JNJ-56136379 tablets will be administered orally.
Trial: NCT03982186
Drug: Nucleos(t)ide Analog (NA)
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
Trial: NCT04247815
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet manufactured to match ATI-450 in appearance
Trial: NCT04247815
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5 mg to 25 mg weekly
Trial: NCT02593110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00549744
Drug: GSK256066
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04031755
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
Trial: NCT04031755
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
Trial: NCT01192867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally QD for 56 weeks
Trial: NCT01192867
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
Trial: NCT01192867
Drug: Antipshychotics (Standard of Care)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
Trial: NCT02171780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04646876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospective , comparative , double blind study
Trial: NCT00822978
Drug: ACHN-490 Injection vs placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
Trial: NCT00251745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Trial: NCT04202380
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Azithromycin orally 1000 mg
Trial: NCT04202380
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 mg orally once
Trial: NCT04202380
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 250 mg orally daily for 4 days
Trial: NCT03071276
Drug: methotrexate/hydrocortisone/cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
Trial: NCT00426439
Drug: Artemether-lumefantrine (Coartem)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
Trial: NCT01748929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04429516
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule containing Microcrystalline Cellulose Ph. Eur, 5 mg twice daily
Trial: NCT02732418
Drug: Depo-Provera CI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
Trial: NCT02732418
Drug: Depo-subQ 104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
Trial: NCT04137042
Drug: Balanced crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative fluid therapy is administrated by using balanced crystalloid
Trial: NCT00262665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
Trial: NCT02216097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet taken once daily for 7 days.
Trial: NCT02500602
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill
Trial: NCT02170649
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02445599
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally 100 mg Diclofenac, administered 1 hour before surgery
Trial: NCT02445599
Drug: bucain + fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
Trial: NCT02445599
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2nd choice for rescue analgetic 250ml intravenously
Trial: NCT03654755
Drug: ASN002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of ASN002 for up to 110 weeks
Trial: NCT04302012
Drug: Mydriatic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects may be administered mydriatic medication to dilate their pupils.
Trial: NCT01453179
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
Trial: NCT02908087
Drug: Victoza® (liraglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
Trial: NCT02908087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
Trial: NCT02307773
Drug: Case Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
Trial: NCT04479644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given intravenously
Trial: NCT03939663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch pills manufactured to mimic misoprostol 200 mg tablets
Trial: NCT00797589
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02523300
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
Trial: NCT00226980
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00679133
Drug: MGCD265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily administration; 7 days on / 7 days off
Trial: NCT00732485
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, sugar pill, from admission to 6 months post burn
Trial: NCT00451178
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Trial: NCT00451178
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2, IV, Day 1 every 21 days, six 21-day cycles
Trial: NCT03189992
Drug: Bushen-Jianpi Dedoction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A traditional chinese medicine prescription
Trial: NCT03452137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
Trial: NCT02152605
Drug: UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
Trial: NCT02152605
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
Trial: NCT02271347
Drug: CMX001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
Trial: NCT03632915
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT04898101
Drug: Microtracer [14C]ACP-196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
Trial: NCT03750552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, QD
Trial: NCT00299650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological serum infusion
Trial: NCT02367911
Drug: 122-0551 Foam
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 122-0551 Foam applied twice daily to treat psoriasis
Trial: NCT02265562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 minutes before the surgery 2 tablet of placebo inserted rectally
Trial: NCT02094417
Drug: AMG531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous, weekly injection
Trial: NCT00912938
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
Trial: NCT00293111
Drug: SDX-101 (R-Etodolac)
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03301649
Drug: Sklice® (Ivermectin) Lotion 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lotion, brand product.
Trial: NCT03583476
Drug: Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
Trial: NCT03929068
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given to maintain blinding of participants and study team.
Trial: NCT06747026
Drug: RT with maintenance of ICI
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.
Trial: NCT06747026
Drug: RT after discontinuation of ICI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.
Trial: NCT00132860
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00674739
Drug: placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo cream applied daily to wart areas for up to 8 weeks
Trial: NCT00108134
Drug: PEP005
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01092858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively